May 28, 2024 – Page 10 – Goldea Capital

Atrion Corporation Enters Into Merger Agreement with Nordson Corporation

Written by Customer Service on May 28, 2024. Posted in Mergers And Acquisitions.

ALLEN, Texas, May 28, 2024 (GLOBE NEWSWIRE) — Atrion Corporation (NASDAQ: ATRI), a developer and manufacturer of products primarily for medical applications, today announced that it has entered into an agreement and plan of merger with Nordson Corporation pursuant to which Nordson will acquire Atrion for $460 per share in cash, representing a total equity value of approximately $815 million. The transaction enterprise value reflects a multiple of 20.2 times Atrion’s 2023 EBITDA, and the $460 per share price represents a 15% premium to Atrion’s 90-day average daily volume-weighted average stock price. The proposed transaction was unanimously approved by the Boards of Directors of Atrion and Nordson. David Battat, President and CEO of Atrion said, “The multiple of over twenty times Atrion’s 2023 EBITDA reflects the substantial value...

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024

Written by Customer Service on May 28, 2024. Posted in Public Companies.

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024 Global Healthcare Conference, taking place in-person in New York on June 5-6, 2024. The fireside chat will take place on Wednesday, June 5 at 3:30 PM (ET). A webcast of the fireside chat will be available at https://wsw.com/webcast/jeff302/aciu/1825568 as well as on the Events Page of AC Immune’s website. A replay will be archived in the same location. Please contact your Jefferies representative...

Predictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Written by Customer Service on May 28, 2024. Posted in Public Companies.

Study successfully demonstrated Predictive’s ability to build AI multi-omic machine learning models to predict survival outcomes among ovarian cancer patients better than clinical data alone PITTSBURGH, May 28, 2024 (GLOBE NEWSWIRE) — Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that positive results from a retrospective study that the company recently completed in collaboration with UPMC Magee-Womens Hospital will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31-June 4, 2024, in Chicago, Il. The purpose of the study was to determine if Predictive Oncology could leverage its artificial intelligence and other capabilities to develop machine learning (ML) models that could more accurately predict both short-term...

Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer

Written by Customer Service on May 28, 2024. Posted in Public Companies.

Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointments of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phiasivongsa, Ph.D., as chief technical officer of Nurix. “I am delighted to announce the promotions of both Paula and Pasit, which recognize their significant and ongoing leadership in advancing our pipeline of novel medicines and particularly in accelerating our NX-5948 program in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma,” said Arthur T. Sands, M.D., Ph.D., president and chief executive officer...

FactSet Schedules Third Quarter 2024 Earnings Call

Written by Customer Service on May 28, 2024. Posted in Public Companies.

NORWALK, Conn., May 28, 2024 (GLOBE NEWSWIRE) — FactSet (NYSE: FDS | NASDAQ: FDS), a global financial digital platform and enterprise solutions provider, announced today that it will release its financial and operating results for the third quarter fiscal 2024, ending May 31, 2024 on Friday, June 21, 2024. FactSet will also host a conference call to discuss these results at 11:00 a.m. Eastern Time on Friday, June 21, 2024. The following information is provided for investors who would like to participate in the conference call: Third Quarter Fiscal 2024 Conference Call Details Date: Friday, June 21, 2024 Time: 11:00 a.m. Eastern Time Participant Registration: FactSet Q3 2024 Earnings Call Registration Please register for the conference call using the above link before the call start time. The conference call platform...

New Opportunity for the Wilson Project

Written by Customer Service on May 28, 2024. Posted in Public Companies.

VAL-D’OR, Quebec, May 28, 2024 (GLOBE NEWSWIRE) — Cartier Resources Inc. (TSXV: ECR, FSE: 6CA) (the “Company”) announces the termination, effective May 23, 2024, of the option agreement (Original Agreement, April 22nd 2021 and Amended Agreement, April 20th 2023) pertaining to its 100% owned Wilson Property, situated 15 km east of Lebel-sur-Quévillon, due to the third anniversary earn-in commitments not being met by the optionor, which was notified accordingly. The project has three key exploration success components: Location Mining camp jurisdiction of Quebec, Canada Infrastructures and qualified workers High grade gold mineralization Trench and drill hole with multiple high grade gold intersections High grade gold Toussaint Deposit open below 200 m Blue-sky Numerous high grade gold discoveries with expansion potential Compilation...

Mobilicom Secures Another Follow-On Order from the U.S. Defense Industry

Written by Customer Service on May 28, 2024. Posted in Public Companies.

Production scale order from a U.S. based Tier-1 defense & drone manufacturer for Mobilicom’s solution integration into drone platforms deployed with a growing slate of end-users Shoham, Israel, May 28, 2024 (GLOBE NEWSWIRE) — Mobilicom Limited (Nasdaq: MOB, MOBBW), a provider of cybersecurity and robust solutions for drones and robotics, today announced it has received a third consecutive commercial scale order from a U.S.-based Tier-1 customer, one of the largest drone manufacturers in the world. The customer purchased Mobilicom’s SkyHopper PRO, a bi-directional cybersecure Software Defined Radio (SDR) datalink system, which has been designed into the customer’s drone platform that is being manufactured for the U.S. Department of Defense (DoD), the broader U.S. defense industry, and other U.S. federal agencies. “We are pleased...

Telix Submits NDA for New Prostate Cancer Imaging Agent

Written by Customer Service on May 28, 2024. Posted in Public Companies.

MELBOURNE, Australia, May 28, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX007-CDx, a new and proprietary cold kit (“Kit”) for the preparation of PSMA-PET imaging1 for prostate cancer. Subject to regulatory approval, this Kit will enable use of a PSMA imaging product with a considerably extended distribution profile compared to currently approved gallium-68 (68Ga) PSMA-PET imaging agents. The Kit’s innovative properties are designed to facilitate more flexible production, including with 68Ga sourced from both newer high activity generators and cyclotrons powered by the ARTMS® QUANTM Irradiation System™2 and GE FASTlab™3 solid and liquid target production...

Treace to Present at Truist Securities MedTech Conference

Written by Customer Service on May 28, 2024. Posted in Public Companies.

Tuesday, June 18, 2024 at 8:00 am Eastern Time PONTE VEDRA, Fla., May 28, 2024 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Truist Securities MedTech Conference on Tuesday, June 18, 2024, beginning at approximately 8:00 am Eastern Time. A live webcast and replay of the fireside chat will be available on the Company’s investor relations website at https://investors.treace.com/. Internet Posting of Information Treace routinely posts information that...

Creative Realities Closes on New Revolving Credit Facility

Written by Customer Service on May 28, 2024. Posted in Public Companies.

LOUISVILLE, Ky., May 28, 2024 (GLOBE NEWSWIRE) — Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage and media solutions, today announced that it and First Merchants Bank (“FMB”) executed a credit agreement implementing the previously-announced $22.1 million senior secured revolving credit facility (the “Revolver”) with a $5 million accordion feature. At closing, the Revolver was utilized to pay off all existing indebtedness of the Company – $13.6 million – along with closing costs and ancillary fees. Additional terms were disclosed in the Company’s Current Report on Form 8-K filed with the SEC on the date of this release. “We are pleased to announce that a new credit facility with First Merchants, as anticipated, has been consummated, paving the way for...

Day: May 28, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice